股本结构
单位：万股
| 公告日期 | 2024-03-11 | 2024-03-07 | 2024-03-07 | 2023-11-07 | 2023-11-07 | 2023-08-02 |
|---|---|---|---|---|---|---|
| 证券总股本 | 6149.76 | 5794.36 | 5782.06 | 5715.07 | 5709.25 | 5697.16 |
| 普通股本 | 6149.76 | 5794.36 | 5782.06 | 5715.07 | 5709.25 | 5697.16 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-13 | 2024-03-01 | 2023-12-31 | 2023-11-03 | 2023-09-30 | 2023-07-28 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-03-11 | 6149.76 | 未披露 |
更多>>
Common stock offered 3,554,000 shares by the company
|
2024-03-13 |
| 2024-03-07 | 5794.36 | 未披露 | 定期报告 | 2024-03-01 |
| 2024-03-07 | 5782.06 | 未披露 |
更多>>
From December 31,2022 to December 31,2023
Issuance of common stock in connection with the incentive equity plan
Issuance of common stock in connection with Symatese Europe Agreement
|
2023-12-31 |
| 2023-11-07 | 5715.07 | 未披露 | 定期报告 | 2023-11-03 |
| 2023-11-07 | 5709.25 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock in connection with the incentive equity plan
|
2023-09-30 |
| 2023-08-02 | 5697.16 | 未披露 | 定期报告 | 2023-07-28 |
| 2023-08-02 | 5693.78 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock in connection with the incentive equity plan
|
2023-06-30 |
| 2023-05-09 | 5692.28 | 未披露 | 定期报告 | 2023-05-05 |
| 2023-05-08 | 5690.09 | 未披露 | 定期报告 | 2023-04-21 |
| 2023-05-08 | 5688.57 | 未披露 | 定期报告 | 2023-04-11 |
| 2023-05-09 | 5688.33 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock in connection with the incentive equity plan
|
2023-03-31 |
| 2023-03-08 | 5641.17 | 未披露 | 定期报告 | 2023-03-03 |
| 2023-03-08 | 5626.06 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock in connection with the incentive equity plan
|
2022-12-31 |
| 2022-11-08 | 5624.66 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-08 | 5618.34 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock in connection with the incentive equity plan
|
2022-09-30 |
| 2022-08-02 | 5609.48 | 未披露 | 定期报告 | 2022-07-29 |
| 2022-08-02 | 5606.34 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock in connection with the incentive equity plan
|
2022-06-30 |
| 2022-05-10 | 5604.90 | 未披露 | 定期报告 | 2022-05-06 |
| 2022-04-29 | 5604.52 | 未披露 | 定期报告 | 2022-04-22 |
| 2022-04-29 | 5604.50 | 未披露 | 定期报告 | 2022-04-12 |
| 2022-05-10 | 5604.14 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock in connection with the incentive equity plan
|
2022-03-31 |
| 2022-03-03 | 5569.45 | 未披露 | 定期报告 | 2022-02-28 |
| 2022-03-03 | 5557.70 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock in connection with litigation settlement
Issuance of common stock for conversion of convertible note
Issuance of common stock upon follow-on offering, net of issuance costs
Issuance of common stock under “at-the-market” (ATM) program
Issuance of common stock in connection with the incentive equity plan
|
2021-12-31 |
| 2021-11-02 | 5557.70 | 未披露 | 定期报告 | 2021-10-29 |
| 2021-11-02 | 5555.38 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with the incentive equity plan
Issuance of common stock under “at-the-market” (ATM) program
|
2021-09-30 |
| 2021-08-04 | 5457.62 | 未披露 | 定期报告 | 2021-08-02 |
| 2021-08-04 | 5437.28 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock upon follow-on offering, net of issuance costs
Issuance of common stock under“at-the-market”(ATM) program
Issuance of common stock in connection with the incentive equity plan
|
2021-06-30 |
| 2021-05-12 | 5412.03 | 未披露 | 定期报告 | 2021-05-07 |
| 2021-04-26 | 5264.87 | 未披露 |
更多>>
1.Common stock offered by the company 9,000,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 33,749,228 shares of common stock outstanding as of December 31, 2020, plus 6,762,652 shares of common stock issued to Medytox pursuant to the Medytox/Allergan Settlement Agreements and 3,136,869 shares of common stock issued to Daewoong pursuant to the Conversion Agreement.
|
2021-04-26 |
| 2021-04-26 | 4377.03 | 未披露 | 定期报告 | 2021-04-23 |
| 2021-04-26 | 4373.78 | 未披露 | 定期报告 | 2021-04-12 |
| 2021-05-12 | 4373.70 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of common stock in connection with litigation settlement
Issuance of common stock for conversion of convertible note
Issuance of common stock in connection with the incentive equity plan
|
2021-03-31 |
| 2021-03-25 | 4373.33 | 未披露 | 定期报告 | 2021-03-25 |
| 2020-10-29 | 3374.92 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock in connection with the incentive equity plan
|
2020-09-30 |
| 2020-08-10 | 3374.85 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock in connection with the incentive equity plan
|
2020-06-30 |
| 2020-05-11 | 3372.85 | 未披露 | 定期报告 | 2020-05-08 |
| 2020-05-11 | 3372.80 | 未披露 |
更多>>
From December 31, 2019 to February 21, 2020
Issuance of common stock in connection with the incentive equity plan
|
2020-02-21 |
| 2020-02-25 | 3356.27 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common stock in connection with the incentive equity plan
Issuance of common stock upon follow-on offering, net of issuance costs
|
2019-12-31 |
| 2019-11-12 | 3264.22 | 未披露 | 定期报告 | 2019-11-12 |
| 2019-11-04 | 2742.52 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common stock in connection with the incentive equity plan
|
2019-09-30 |
| 2019-08-12 | 2742.45 | 未披露 | 定期报告 | 2019-08-06 |
| 2019-08-12 | 2739.30 | 未披露 |
更多>>
from March 31, 2019 to June 30,2019
Issuance of common stock in connection with the incentive equity plan
|
2019-06-30 |
| 2019-05-15 | 2737.30 | 未披露 | 定期报告 | 2019-05-13 |
| 2019-04-29 | 2733.30 | 未披露 | 定期报告 | 2019-04-23 |
| 2019-04-10 | 2728.58 | 未披露 | 定期报告 | 2019-04-09 |
| 2019-05-01 | 2728.54 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of common stock in connection with the incentive equity plan
|
2019-03-31 |
| 2019-03-20 | 2727.50 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Preferred stock conversion upon initial public offering
Issuance of common stock upon initial public offering, net of issuance costs
Issuance of common stock upon follow-on offering, net of issuance costs
Issuance of common stock in connection with the incentive equity plan
|
2018-09-30 |
| 2018-08-02 | 2667.50 | 未披露 | 定期报告 | 2018-08-01 |
| 2018-08-02 | 2367.50 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-07-16 | 2367.50 | 未披露 | 定期报告 | 2018-06-29 |
| 2018-05-10 | 2364.04 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-29 | 2364.04 | 未披露 | 定期报告 | 2018-03-23 |
| 2018-02-09 | 2359.29 | 未披露 |
更多>>
1.Common stock offered 5,000,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 18,592,875 shares of common stock outstanding as of September 30, 2017
3.a 1.6527-for-one forward stock split of our common stock effected on January 26, 2018
|
2018-02-08 |
| 2018-01-29 | 1652.70 | 125.00 | 定期报告 | 2015-12-31 |
Common stock offered 3,554,000 shares by the company
From December 31,2022 to December 31,2023
Issuance of common stock in connection with the incentive equity plan
Issuance of common stock in connection with Symatese Europe Agreement
From June 30, 2023 to September 30, 2023
Issuance of common stock in connection with the incentive equity plan
From March 31, 2023 to June 30, 2023
Issuance of common stock in connection with the incentive equity plan
From December 31, 2022 to March 31, 2023
Issuance of common stock in connection with the incentive equity plan
From December 31, 2021 to December 31, 2022
Issuance of common stock in connection with the incentive equity plan
From June 30, 2022 to September 30, 2022
Issuance of common stock in connection with the incentive equity plan
From March 31, 2022 to June 30, 2022
Issuance of common stock in connection with the incentive equity plan
From December 31, 2021 to March 31, 2022
Issuance of common stock in connection with the incentive equity plan
From December 31, 2020 to December 31, 2021
Issuance of common stock in connection with litigation settlement
Issuance of common stock for conversion of convertible note
Issuance of common stock upon follow-on offering, net of issuance costs
Issuance of common stock under “at-the-market” (ATM) program
Issuance of common stock in connection with the incentive equity plan
From June 30, 2021 to September 30, 2021
Issuance of common stock in connection with the incentive equity plan
Issuance of common stock under “at-the-market” (ATM) program
From March 31, 2021 to June 30, 2021
Issuance of common stock upon follow-on offering, net of issuance costs
Issuance of common stock under“at-the-market”(ATM) program
Issuance of common stock in connection with the incentive equity plan
1.Common stock offered by the company 9,000,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 33,749,228 shares of common stock outstanding as of December 31, 2020, plus 6,762,652 shares of common stock issued to Medytox pursuant to the Medytox/Allergan Settlement Agreements and 3,136,869 shares of common stock issued to Daewoong pursuant to the Conversion Agreement.
From December 31, 2020 to March 31, 2021
Issuance of common stock in connection with litigation settlement
Issuance of common stock for conversion of convertible note
Issuance of common stock in connection with the incentive equity plan
From June 30, 2020 to September 30, 2020
Issuance of common stock in connection with the incentive equity plan
From March 31, 2020 to June 30, 2020
Issuance of common stock in connection with the incentive equity plan
From December 31, 2019 to February 21, 2020
Issuance of common stock in connection with the incentive equity plan
from December 31, 2018 to December 31, 2019
Issuance of common stock in connection with the incentive equity plan
Issuance of common stock upon follow-on offering, net of issuance costs
from June 30, 2019 to September 30, 2019
Issuance of common stock in connection with the incentive equity plan
from March 31, 2019 to June 30,2019
Issuance of common stock in connection with the incentive equity plan
from December 31, 2018 to March 31, 2019
Issuance of common stock in connection with the incentive equity plan
from December 31, 2017 to September 30, 2018
Preferred stock conversion upon initial public offering
Issuance of common stock upon initial public offering, net of issuance costs
Issuance of common stock upon follow-on offering, net of issuance costs
Issuance of common stock in connection with the incentive equity plan
1.Common stock offered 5,000,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 18,592,875 shares of common stock outstanding as of September 30, 2017
3.a 1.6527-for-one forward stock split of our common stock effected on January 26, 2018